Indeed, it is likely to speculate that in subjects with higher levels of GRK5, the administration of PLK1 inhibitor could be ineffective and that therapeutic approach based on both PLK1 and GRK5 inhibition, could be more effective than PLK1 inhibition alone, in certain cancer types characterized by hyperactivation of PLK1- signaling. The gene discussed is PLK1; the disease is cancer.